Strategic Asset Divestment HOOKIPA has recently completed the sale of oncology assets to NeoTrail Therapeutics, indicating a potential shift in portfolio strategy and a need to target remaining ARENAVIRAL programs or collaboration opportunities with partners focusing on immunotherapy platforms.

Funding and Valuation Patch With a reported market cap around 22 million and ongoing non-binding discussions to acquire Poolbeg Pharma, there may be heightened M&A and licensing activity in the immunotherapy space, presenting opportunities for strategic partnerships or out-licensing of HOOKIPA's arenavirus platform.

Collaborations with Gilead Active collaboration with Gilead to develop functional cures for HBV and HIV suggests potential for future co-development or licensing deals, as well as interest in complementary technologies that can leverage HOOKIPA’s platform for infectious disease immune modulation.

Pipeline Focus HOOKIPA’s pipeline targets HPV16+ cancers, prostate cancer, and KRAS-mutated cancers, signaling a specialized immunotherapy focus and potential cross-sell or co-development needs with CROs, diagnostic partners, or specialty oncology distributors to reach niche patient populations.

Resource and Scale Gap Given the 11-50 employee base and the clinical-stage nature of the business, there is a clear opportunity for partnerships with contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), and fundraising advisory services to accelerate clinical milestones and scaling.